Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Debt Surge ⢠Margin Pressure ⢠Liquidity Decline BMRN's strong margins and positive cash flow are offset by sharply higher debt, weaker net profitability, and elevated valuation, making deleveraging and earnings recovery key watchpoints.
Price Behavior
Key Price Behavior Insights: ⢠Below moving average ⢠Support breakdown ⢠Resistance rejection Support Level: $64.00â$64.50 Resistance Level: $66.40â$67.00 BMRN is bearish over the last month, with a break below $64â$64.50 support signaling downside risk unless it reclaims $66.40 resistance.
Sentiment & News
Key News Insights: ⢠Royalty settlement ⢠Pipeline expansion ⢠VOXZOGO progress BioMarin strengthened its rare-disease growth outlook through pipeline expansion, VOXZOGO progress, and royalty upside, despite discontinuing its Noonan syndrome program.
AI Summary
BioMarin's investment case now hinges less on VOXZOGO-led growth and more on whether Amicus integration delivers $200â$220 million in synergies, sustained free-cash-flow growth, and deleveraging; with $4.19 billion of debt and a premium valuation, investors should demand proof of cash conversion and improving interest coverage before underwriting further upside.
Description
BioMarin Pharmaceutical is a biopharmaceutical company that develops and sells therapies for rare and serious genetic and metabolic disorders, with marketed treatments across lysosomal storage disorders, phenylketonuria, Batten disease, achondroplasia and related conditions. Its late-stage pipeline includes gene therapies for hemophilia A and phenylketonuria and early-stage programs for primary hyperoxaluria, while commercial operations distribute products through specialty pharmacies, hospitals and wholesalers in the U.S., Europe, Latin America and other markets. The company maintains multiple licensing and collaboration arrangements and is headquartered in San Rafael, California, having been founded in 1996.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 22 | Dec 29 | BMRN | BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical raised 2025 revenue guidance on strong product sales and a $4.8B accretive Amicus acquisition, supported by FDA regulatory catalysts and an 18% stock gain over 3 weeks, validating near-term positive momentum. | Closed | +1.3% |